|
WO2021072000A1
|
|
Serum protein biomarker panel for idiopathic pulmonary fibrosis
|
|
US2021098121A1
|
|
Systems and method for analyzing operational rhythms in hospital treatment
|
|
US2021060162A1
|
|
Methods and compositions for the treatment of an inflammatory bowel disease
|
|
WO2021041443A2
|
|
Organoid mesoderm lineage diversification
|
|
WO2021030373A1
|
|
Improved methods for making organoid compositions
|
|
WO2021011800A1
|
|
Method of treating neoplastic diseases with a cdc42-specific inhibitor
|
|
WO2021007593A1
|
|
Compounds useful for inhibiting bfl1 and their use in therapy
|
|
WO2021007383A1
|
|
Modified cells and related methods
|
|
WO2021003222A1
|
|
Pancreas-on-a-chip and uses thereof
|
|
WO2020252487A1
|
|
Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
|
|
WO2020247703A1
|
|
Methods and compositions for treatment of neurodegeneration
|
|
WO2020243615A1
|
|
Compositions and methods for cellular reprogramming
|
|
WO2020243633A1
|
|
Shaped organoid compositions and methods of making same
|
|
WO2020243613A1
|
|
Methods of generating and expanding hematopoietic stem cells
|
|
WO2020243446A1
|
|
Methods and compositions for treatment of smith kingsmore syndrome
|
|
WO2020232368A1
|
|
Methods for determining personalized full dose of melphalan in reduced intensity regimen prior to hematopoietic cell transplantation
|
|
US2020352369A1
|
|
Cup insert providing volume and flow regulation
|
|
US2020345712A1
|
|
Compositions and methods for treating cancer
|
|
WO2020223302A1
|
|
Compositions comprising a tweak ligand and methods of using same
|
|
WO2020214676A1
|
|
Viral vector manufacturing methods
|
